



COPY OF PAPERS
ORIGINALLY FILED

#24 1631/11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 18 2002

TECH CENTER 1600/2900

the Application of:

McKENZIE et al.

Serial No.: 09/163,089

Filed: September 29, 1998

Atty. File No.: 4102-1

For: "COMPOSITIONS FOR
IMMUNOTHERAPY AND USES
THEREOF"

Commissioner of Patents
Washington, D.C. 20231

) Group Art Unit: 1631

) Examiner: Oghara, N.

) SUPPLEMENTAL INFORMATION
) DISCLOSURE STATEMENT

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE
ADDRESSED TO THE ASSISTANT COMMISSIONER FOR
PATENTS, WASHINGTON, DC 20231 ON 4/14/02
SHERIDAN ROSS P.C.

BY: *Sheridan Ross*

Dear Sir:

Pursuant to Applicants' duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicants hereby submit the enclosed PTO Form 1449. The documents identified herein were of record in U.S. Patent Application Serial No. 08/833,807, now U.S. Patent No. 5,989,552, and since this patent claims priority therefrom, copies of the identified documents are not being submitted under 37 CFR § 1.98(d). Applicants do not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicants that each such document is prior art as to the above-identified patent application.

Also enclosed is a check in the amount of \$180 pursuant to 37 CFR § 1.97(c).

Respectfully submitted,

SHERIDAN ROSS P.C.

04/17/2002 CNGUYEN 00000117 09163089

01 FC:126

180.00 OP

By: *Angela Dallas*

Angela K. Dallas
Registration No. 42,460
1560 Broadway, Suite 1200
Denver, CO 80202-5141
(303) 863-9700

Date: *April 17, 2002*